Subsequent Bevacizumab Treatment in Patients With HHT After the End of BABH Interventional Study. A Descriptive Study.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 3
- 主要终点
- Bevacizumab treatment description after end of BABH study
研究概览
简要总结
Bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in HHT.
We studied the efficacy of bevacizumab on severe bleeding in HHT patients in a randomized study recently published (NCT03227263, J Int Med 2023). In this study, 24 patients were included, 12 patients received bevacizumab and 12 patients received placebo. The duration of patient participation was 6 months, including the 2.5-month treatment period and 3.5 month follow-up after treatment.
We describe the evolution of the number of RBC transfused in HHT patients who received bevacizumab during the year after the end of the study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient included in BABH study
排除标准
- •Patients opposition
结局指标
主要结局
Bevacizumab treatment description after end of BABH study
时间窗: 12 months
Number of patients who received bevacizumab after BABH study. Among patients who received bevacizumab in BABH study: description of re-treatments. In patients who received placebo in BABH study: description of treatments.
次要结局
未报告次要终点